2023 World Conference on Lung Cancer (Posters)-EP12.01. Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity

EP12.01. Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity - PDF(Slides)

Back to course

Pdf Summary

This study is a retrospective cohort study conducted in Indonesia to investigate the clinical risk factors affecting the progression-free survival (PFS) of patients with EGFR-positive mutation non-small cell lung cancer (NSCLC) who were treated with first-line afatinib. The study included a total of 103 patients who were enrolled between January 2017 and December 2021.<br /><br />The results of the study showed that poor ECOG performance status (PS) was a significant independent factor associated with poor PFS in EGFR-positive mutation NSCLC patients treated with afatinib. However, other demographic characteristics such as gender, race, family history of cancer, staging, brain metastasis, EGFR mutations, and toxicities did not have a significant effect on PFS and overall survival (OS).<br /><br />The median age of the patients was 58.8 years, and 50.5% were female. Never smoker patients accounted for 46.6% of the overall population. The majority of patients (61.2%) were diagnosed in stage 4A, and 22.3% had an ECOG PS of 2. The most common EGFR mutations were exon 19 deletion and exon 21 L858R, found in 90.3% of patients. The median PFS was 11 months.<br /><br />Female patients had longer PFS compared to male patients, and patients with exon 19 deletion, never smokers, and ECOG PS 0-1 had the longest PFS of 12.6 months. On the other hand, patients with poor ECOG PS had the shortest PFS of 8.3 months.<br /><br />Overall, the study suggests that poor ECOG PS is a significant factor associated with poor PFS in EGFR-positive mutation NSCLC patients treated with first-line afatinib. These findings can help in identifying patients who may benefit from alternative treatment strategies or closer monitoring.

Asset Subtitle

Suryanti Pratiwi

Meta Tag

Speaker Suryanti Pratiwi

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective cohort study

Indonesia

clinical risk factors

progression-free survival

EGFR-positive mutation

non-small cell lung cancer

NSCLC

first-line afatinib

ECOG performance status

median age